<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The colony-stimulating factors (CSFs) are <z:chebi fb="0" ids="25905">polypeptide hormones</z:chebi> that regulate <z:e sem="disease" ids="C1513644" disease_type="Neoplastic Process" abbrv="">myeloid proliferation</z:e> and differentiation </plain></SENT>
<SENT sid="1" pm="."><plain>Granulocyte-macrophage CSF (GM-CSF) has been used in leukopenic acquired <z:hpo ids='HP_0002721'>immunodeficiency</z:hpo> syndrome (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>) patients, <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients, and <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients after intensive chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Its hematologic activity results in an increase in neutrophil, monocyte, and eosinophil counts </plain></SENT>
<SENT sid="3" pm="."><plain>Recombinant GM-CSF effectively restores granulopoiesis in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> patients and appears capable of improving myelopoiesis and, in some cases, erythropoiesis in subjects with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>It accelerates bone marrow recovery after chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Similarly, granulocyte CSF has demonstrated the capacity to reduce the granulocyte nadir after single agent or combination chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, CSFs have considerable promise for therapy for <z:hpo ids='HP_0005528'>bone marrow failure</z:hpo> states </plain></SENT>
</text></document>